ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck KGaA has agreed to acquire Exelead, an Indianapolis-based firm specializing in lipid nanoparticle (LNP)–based drug delivery technology. LNPs are a key part of messenger RNA (mRNA) therapeutics targeting COVID-19 and other diseases. The $780 million deal follows Merck’s acquisition last year of the mRNA maker AmpTec. Merck is also increasing its output of lipids, which it supplies for production of the Pfizer-BioNTech COVID-19 vaccine.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter